https://www.tikr.com/blog/pfizers-lyme-vaccine-just-cleared-eu-review-is-the-stock-already-priced-in
Pfizer’s Lyme Vaccine Just Cleared EU Review. Is the Stock Already Priced In?
Gian Estrada•6 minute read
Reviewed by:David Hanson
Last updated Aug 17, 2026

MerinoPhotos and Max Mishin from Pexels
Key Takeaways for Pfizer Stock as of August 2026
- Lyme Validation: The European Medicines Agency validated the marketing application for Pfizer and partner Valneva’s Lyme disease vaccine candidate PF-07307405 on August 14, starting the formal EU review with a possible US filing later this year.
- Street Split: Pfizer stock carries 8 buys, 2 outperforms, 16 holds, 1 underperform, and 1 sell among 26 analysts, with a $29 mean target sitting 7% above the $27 close.
- Model Gap: TIKR pegs Pfizer stock at $29 by 2030, a 9% return.
- Insider Buying: CEO Albert Bourla bought $1.0M of stock at $26.34 in mid-August while director Mortimer Buckley added $960K at $25.52 days earlier, two of the largest insider purchases logged this year.
Pfizer Stock’s Lyme Vaccine Just Cleared Its First EU Hurdle
Pfizer (PFE) stock’s Lyme disease vaccine program took a real step forward on August 14, when the European Medicines Agency validated the marketing authorization application for candidate PF-07307405, developed with French vaccine maker Valneva. Validation starts the formal EU review clock. It doesn’t guarantee approval, but it confirms the dossier is complete enough for regulators to evaluate.
The filing rests on Phase 3 VALOR data showing more than 70% efficacy in people aged five and older, with no safety concerns identified. Valneva shares jumped 15.6% on the news, its best single-day move since August 2025. Kempen analysts called the Lyme program “the key” driver of the investment case and flagged a possible US filing from Pfizer in the second half of 2026, with a US approval decision potentially landing in the second half of 2027. (See link for article)
_______________
**Comment**
If you haven’t felt the vibe yet, I’ll clue you in: it’s all about money. Nothing whatsoever to do with health.
When it comes to ‘vaccines,’ never expect a straight, transparent answer. Just don’t. Then, you won’t be disappointed.
‘Vaccines’ are by far the biggest cash cow for Big Pharma. Just read the article & learn that Pfizer’s own CEO bought $1.0M of stock at $26.34 in mid-August while director Mortimer Buckley added $960K at $25.52 days earlier, two of the largest insider purchases logged this year. This should be illegal.
Further, you can’t create a ‘vaccine’ for a chronic/relapsing illness, which is often complicated by numerous coinfections, none of which are in the vaccine, – which is exactly what Lyme/MSIDS is, despite public health ‘authorities’ and bought out researchers claims. It’s also created with the very same OspA protein which caused people that took the Lymerix vaccine to develop debilitating chronic Lyme symptoms. The claim that it was removed due to ‘lack of demand,’ only tells part of the story. Nobody wanted an injection that made them sick!
For a refresher course on the Lyme vaccine:
- https://madisonarealymesupportgroup.com/2026/05/26/new-lyme-vaccine-how-much-bs-can-we-tolerate/
- https://madisonarealymesupportgroup.com/2026/03/24/pfizer-valneva-lyme-disease-vaccine-falls-short-as-low-cases-skew-results/
- https://madisonarealymesupportgroup.com/2026/04/20/pfizer-reboots-lyme-vaccine-linked-to-lyme-disease-like-autoimmune-arthritis-and-class-action-lawsuits/
- https://madisonarealymesupportgroup.com/2026/03/10/valnevas-strategic-bet-lyme-vaccine-holds-their-key-to-the-future-but-not-yours/
- https://madisonarealymesupportgroup.com/2023/09/07/dog-dies-minutes-after-lyme-vaccine-ospa-mrna-vaccine-in-the-works-for-humans/
- https://madisonarealymesupportgroup.com/2020/02/10/the-bitter-feud-over-lymerix/
- https://madisonarealymesupportgroup.com/2018/01/28/the-secret-x-files-the-untold-history-of-the-lymerix-vaccine/
- https://madisonarealymesupportgroup.com/2023/09/05/the-complex-story-of-the-lyme-disease-vaccine/
- https://madisonarealymesupportgroup.com/2017/09/07/20268/ New Lyme Vaccine Coming Soon Caveat Empter – Buyer Beware!
- https://www.mdpi.com/2077-0383/15/4/1634 Our experience with prior Lyme disease vaccines suggests that even an effective vaccine would not fully reduce the incidence of human disease. Importantly, vaccination against Borrelia genospecies would not affect tick abundance or exposure risk. It would also not mitigate the transmission of other tick-borne pathogens that are proliferating in human-biting ticks. In addition to infectious diseases, ticks are associated with non-infectious conditions such as tick paralysis and alpha-gal syndrome that will not be affected by a Lyme disease vaccine.
